Role of Urokinase-Type Plasminogen Activator and Tumor-Associated Trypsinogen in pancreatic cancer metastasis

Main Article Content

Dunia Tahseen Nema Al-Aridhi
Firas Hassan
Tania T. Alaridhi

Keywords

Proteolysis, pancreatic cancer, u-PA, TAT

Abstract

The Tumor-Associated Trypsinogen “TAT” and Urokinase-Type Plasminogen Activator “u-PA” perform a controlling function in the devolution of “extracellular matrix” through the infestation operation of tumor. Modifying evolution factor beta-1 is a multifunctional poly-peptide that reveals cell evolution and discrimination, the “extracellular matrix deposition,” “cellular adhesion possession,”emd,cap, and also “angiogenesis.”a. Receptor which is splinter and vigorous by trypsin and tryptase. We formerly state that “TGF-beta-1” upregulated “vascular endothelial growth factor” (VEGF) fabrication and protease innovation “u-PA” in the highly metastatic pancreatic cancer cell lines of “Sw1990” and “Capan-2.”

Abstract 118 | pdf Downloads 134

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.https://doi.org/10.3322/caac.21492
2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74: 2913–2921.https://doi.org/10.1158/0008-5472.CAN-14-0155
3. Vujasinovic M, Valente R, Del Chiaro M, et al.Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017; 9: 183.
https://doi.org/10.3390/nu9030183
4. Pezzilli R. Applicability of a checklist for the diagnosis and treatment of severe exocrine pancreatic insufficiency: a survey on the management of pancreatic maldigestion in Italy. Panmin Med. 2016;58: 245–252.
5. Fadhil OK, and Hassan FA. Role of LDH, 17-βhydroxysteroid dehydrogenase and myloperoxidase enzymesin early diagnosis for lung cancer patients. Int J Pharmaceut Res. 2020; 14(Suppl. 1).
6. Hassan F, Al-Saffar AZ, and Al-Shanon AF. Antioxidant enzymes level detection in Cisplatin treated Iraqi lung cancer patients and in vitro
estimating the cytotoxic and reactive oxygen species generation in A549 cell line. Int J Pharmaceut Qual Assur. 2020; 10(1): 32–37.
https://doi.org/10.25258/ijpqa.11.1.5
7. Woods NK, and Padmanabhan J. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity inpancreatic cancer cells. J Biol Chem. 2013; 288(42): 30114–30124. https://doi.org/10.1074/jbc.M113.459255
8. Williams SJ, Gotley DC, and Antalis TM. Human trypsinogen in colorectal cancer. Int J Cancer. 2001; 93: 67–73. https://doi.org/10.1002/ijc.1304
9. Uchima Y, Sawada T, Nishihara T, et al. Identification of a trypsinogen activity stimulating factor produced by pancreatic cancer cells: its role
in tumor invasion and metastasis. Int J Mol Med. 2003; 12: 871–878. https://doi.org/10.3892/ijmm.12.6.871
10. Tajima H, Ohta T, Elnemr A, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA. Int J Cancer. 2001; 94: 699–704. https://doi.org/10.1002/ijc.1531
11. Akhurst RJ, and Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol. 1999; 187: 82–90.
https://doi.org/10.1002/(SICI)1096-9896(199901)187:1%3C82::AIDPATH248%3E3.0.CO;2-8